Amphista Therapeutics Dosed First BRAMLIE Trial Patient
The clinical trial will evaluate the safety and efficacy of the Targeted Glue degrader AMX-883.
Updated on Oct. 12, 2026 in Cancer
Live Poll
Should medical research prioritize broad-acting drugs over treatments targeted to specific patient mutations?
Amphista Therapeutics has officially dosed the first patient in its Phase 1 BRAMLIE clinical trial. The study is investigating the safety and preliminary efficacy of AMX-883, an orally bioavailable therapeutic for patients with AML and high-risk MDS.
Why it matters
Current targeted agents for AML are restricted to specific mutations, limiting treatment options for many patients. AMX-883 is designed to act as a broad-acting therapeutic intended to serve diverse subtypes of the disease.
The BRAMLIE trial is expected to enroll approximately 54 participants to test the drug candidate. Acute myeloid leukemia currently carries a five-year survival rate of 33%.
The players
Amphista Therapeutics
This is a biopharmaceutical company specializing in the development of targeted protein degradation therapeutics.
U.S. Food and Drug Administration
This federal agency is responsible for protecting public health by regulating the safety and efficacy of drugs and clinical trials.
The details
AMX-883 functions as a Targeted Glue degrader that recruits the E3 ligase DCAF16 to induce the degradation of BRD9. The trial will focus on evaluating patient safety, pharmacokinetics, and the drug's preliminary efficacy as a monotherapy.
Timeline
The FDA authorized the BRAMLIE trial in June 2026.
The first patient was dosed on October 12, 2026.
The Big Picture
The BRAMLIE Phase 1 trial represents an evolution in medical research by moving beyond mutation-specific treatments. This approach reflects a broader scientific shift toward using targeted protein degradation to address complex oncological conditions.
This trial offers a new experimental treatment option for individuals diagnosed with AML or high-risk MDS. Patients and their care teams may discuss the study requirements with their oncologists to determine if they qualify for enrollment.
The takeaway
The study of AMX-883 highlights a significant transition toward broader-acting treatments for aggressive blood cancers. Patients interested in emerging clinical trials should consult with medical professionals about current eligibility criteria.
What happens next
A multi-center dose-escalation study is planned to evaluate AMX-883 in combination with standard care.
Further reading
Learn more about the latest research in this field at the Cancer section.
Live Poll
Should medical research prioritize broad-acting drugs over treatments targeted to specific patient mutations?
